Literature DB >> 11849704

Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum.

Esmeralda Vargas-Serrato1, John W Barnwell, Paul Ingravallo, Francine B Perler, Mary R Galinski.   

Abstract

Plasmodium vivax merozoite surface protein-9 (Pvmsp-9) is characterized here along with orthologues from the related simian malarias Plasmodium cynomolgi and Plasmodium knowlesi. We show that although the corresponding MSP-9 proteins do not have acidic-basic repeated amino acid (aa) motifs, they are related to the Plasmodium falciparum acidic-basic repeat antigen (ABRA) also known as p101. Recognition of this new interspecies Plasmodium MSP family stems from the prior identification of related MSP termed PvMSP-185, PcyMSP-150, and PkMSP-110 on the surface of P. vivax, P. cynomolgi and P. knowlesi merozoites. A clone containing the nearly complete P. knowlesi gene encoding PkMSP-110/MSP-9 provided a hybridization probe and initial sequence information for the design of primers to obtain the P. vivax and P. cynomolgi orthologues using polymerase chain reaction (PCR) amplification strategies. The P. vivax, P. cynomolgi and P. knowlesi msp-9 genes encode proteins that range in calculated molecular mass from 80 to 107 kDa, have typical eukaryotic signal peptides and diverse repeated motifs present immediately upstream of their termination codon. Another feature conserved among these proteins, including the P. falciparum ABRA protein, is the positions of four cysteine residues near the N-terminus, suggesting this conservation maintains structural and perhaps functional characteristics in the MSP-9 family. Rabbit polyclonal antisera raised against recombinantly expressed N-termini of P. knowlesi and P. vivax MSP-9 cross-react with the counterpart proteins in immunofluorescence and immunoblot assays. Comparative interspecies investigations of the potential role(s) of Plasmodium MSP-9 in merozoite invasion of erythrocytes and as a malaria vaccine candidate can now be pursued.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849704     DOI: 10.1016/s0166-6851(01)00433-9

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  18 in total

1.  Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10.

Authors:  Yang Cheng; Bo Wang; Jetsumon Sattabongkot; Chae Seung Lim; Takafumi Tsuboi; Eun-Taek Han
Journal:  Parasitol Res       Date:  2014-04-25       Impact factor: 2.289

2.  Genetic diversity of Plasmodium vivax malaria in China and Myanmar.

Authors:  Daibin Zhong; Mariangela Bonizzoni; Guofa Zhou; Guangze Wang; Bin Chen; Anne Vardo-Zalik; Liwang Cui; Guiyun Yan; Bin Zheng
Journal:  Infect Genet Evol       Date:  2011-05-23       Impact factor: 3.342

3.  The evolution and diversity of a low complexity vaccine candidate, merozoite surface protein 9 (MSP-9), in Plasmodium vivax and closely related species.

Authors:  Stella M Chenet; M Andreína Pacheco; David J Bacon; William E Collins; John W Barnwell; Ananias A Escalante
Journal:  Infect Genet Evol       Date:  2013-09-14       Impact factor: 3.342

Review 4.  Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Authors:  Francis B Ntumngia; Christopher L King; John H Adams
Journal:  Int J Parasitol       Date:  2012-10-12       Impact factor: 3.981

5.  Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals.

Authors:  J C Lima-Junior; T M Tran; E V S Meyer; B Singh; S G De-Simone; F Santos; C T Daniel-Ribeiro; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

6.  Antibodies against MAEBL ligand domains M1 and M2 inhibit sporozoite development in vitro.

Authors:  Peter Preiser; Laurent Rénia; Naresh Singh; Bharath Balu; William Jarra; Tatiana Voza; Osamu Kaneko; Peter Blair; Motomi Torii; Irène Landau; John H Adams
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 7.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

8.  Evolutionary analysis of circumsporozoite surface protein and merozoite surface protein-1 (CSP and MSP-1) sequences of malaria parasites.

Authors:  Vijay Tripathi; Dwijendra Gupta
Journal:  Bioinformation       Date:  2011-07-06

9.  Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area.

Authors:  Josué C Lima-Junior; Rodrigo N Rodrigues-da-Silva; Dalma M Banic; Jianlin Jiang; Balwan Singh; Gustavo M Fabrício-Silva; Luís C S Porto; Esmeralda V S Meyer; Alberto Moreno; Maurício M Rodrigues; John W Barnwell; Mary R Galinski; Joseli de Oliveira-Ferreira
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

Review 10.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.